Next, we randomized the BT-474 and MDA-MB-231 tumor-bearing mice into three groups, where group 1 mice were left untreated, group 2 mice were treated with siRNASCRAM NPs with scrambled siRNA, and group 3 mice were treated with siRNACERK NPs with CERK-targeted siRNA. Here, CERK is linked to neoplasm.